Seth S Martin1,2, Natalie Daya2, Pamela L Lutsey3, Kunihiro Matsushita2, Anna Fretz2, John W McEvoy1,2, Roger S Blumenthal1, Josef Coresh2, Philip Greenland4, Anna Kottgen2,5, Elizabeth Selvin2. 1. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and the Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, Maryland 21205. 3. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota 55454. 4. Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611. 5. Division of Genetic Epidemiology, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
Abstract
Context: Cardiovascular outcomes in mild thyroid dysfunction (treatment controversial) and moderate or severe dysfunction (treatment standard) remain uncertain. Objective: To examine cross-sectional and prospective associations of thyroid function with cardiovascular risk factors and events. Design: In the Atherosclerosis Risk in Communities Study, we measured concentrations of thyrotropin, free thyroxine, and total triiodothyronine (T3) in stored serum samples originally collected in 1990-1992. We used multivariable linear regression to assess cross-sectional associations of thyroid function with cardiovascular risk factors and Cox regression to assess prospective associations with cardiovascular events. Follow-up occurred through 31 December 2014. Setting: General community. Participants: Black and white men and women from the United States, without prior myocardial infarction (MI), stroke, or heart failure. Main Outcomes and Measures: Cross-sectional outcomes were blood pressure, glycemic markers, and blood lipids. Prospective outcomes were adjudicated fatal and nonfatal MI and stroke. Results: Among 11,359 participants (57 ± 6 years, 58% women), thyroid function was more strongly associated with blood lipids than blood pressure or glycemic measures. Mean adjusted differences in low-density lipoprotein cholesterol were +15.1 (95% confidence interval: 10.5 to 19.7) and +3.2 (0.0 to 6.4) mg/dL in those with moderate/severe and mild chemical hypothyroidism, relative to euthyroidism; an opposite pattern was seen in hyperthyroidism. Similar differences were seen in triglycerides and non-high-density lipoprotein cholesterol. With a 22.5-year median follow-up, 1102 MIs and 838 strokes occurred, with similar outcomes among baseline thyroid function groups and by T3 concentrations. Conclusions: Hypothyroidism is associated with hyperlipidemia, but the magnitude is small in mild chemical hypothyroidism, and cardiovascular outcomes are similar between thyroid function groups.
Context: Cardiovascular outcomes in mild thyroid dysfunction (treatment controversial) and moderate or severe dysfunction (treatment standard) remain uncertain. Objective: To examine cross-sectional and prospective associations of thyroid function with cardiovascular risk factors and events. Design: In the Atherosclerosis Risk in Communities Study, we measured concentrations of thyrotropin, free thyroxine, and total triiodothyronine (T3) in stored serum samples originally collected in 1990-1992. We used multivariable linear regression to assess cross-sectional associations of thyroid function with cardiovascular risk factors and Cox regression to assess prospective associations with cardiovascular events. Follow-up occurred through 31 December 2014. Setting: General community. Participants: Black and white men and women from the United States, without prior myocardial infarction (MI), stroke, or heart failure. Main Outcomes and Measures: Cross-sectional outcomes were blood pressure, glycemic markers, and blood lipids. Prospective outcomes were adjudicated fatal and nonfatal MI and stroke. Results: Among 11,359 participants (57 ± 6 years, 58% women), thyroid function was more strongly associated with blood lipids than blood pressure or glycemic measures. Mean adjusted differences in low-density lipoprotein cholesterol were +15.1 (95% confidence interval: 10.5 to 19.7) and +3.2 (0.0 to 6.4) mg/dL in those with moderate/severe and mild chemical hypothyroidism, relative to euthyroidism; an opposite pattern was seen in hyperthyroidism. Similar differences were seen in triglycerides and non-high-density lipoprotein cholesterol. With a 22.5-year median follow-up, 1102 MIs and 838 strokes occurred, with similar outcomes among baseline thyroid function groups and by T3 concentrations. Conclusions: Hypothyroidism is associated with hyperlipidemia, but the magnitude is small in mild chemical hypothyroidism, and cardiovascular outcomes are similar between thyroid function groups.
Authors: John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli Journal: Arch Intern Med Date: 2005-11-28
Authors: W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar Journal: Stroke Date: 1999-04 Impact factor: 7.914
Authors: Ulla T Schultheiss; Alexander Teumer; Marco Medici; Yong Li; Natalie Daya; Layal Chaker; Georg Homuth; Andre G Uitterlinden; Matthias Nauck; Albert Hofman; Elizabeth Selvin; Henry Völzke; Robin P Peeters; Anna Köttgen Journal: J Clin Endocrinol Metab Date: 2015-02-26 Impact factor: 5.958
Authors: Annemieke Roos; Stephan J L Bakker; Thera P Links; Rijk O B Gans; Bruce H R Wolffenbuttel Journal: J Clin Endocrinol Metab Date: 2006-11-07 Impact factor: 5.958
Authors: C Meier; J J Staub; C B Roth; M Guglielmetti; M Kunz; A R Miserez; J Drewe; P Huber; R Herzog; B Müller Journal: J Clin Endocrinol Metab Date: 2001-10 Impact factor: 5.958
Authors: Nicolas Ochs; Reto Auer; Douglas C Bauer; David Nanchen; Jacobijn Gussekloo; Jacques Cornuz; Nicolas Rodondi Journal: Ann Intern Med Date: 2008-05-19 Impact factor: 25.391
Authors: Layal Chaker; Christine Baumgartner; Wendy P J den Elzen; M Arfan Ikram; Manuel R Blum; Tinh-Hai Collet; Stephan J L Bakker; Abbas Dehghan; Christiane Drechsler; Robert N Luben; Albert Hofman; Marileen L P Portegies; Marco Medici; Giorgio Iervasi; David J Stott; Ian Ford; Alexandra Bremner; Christoph Wanner; Luigi Ferrucci; Anne B Newman; Robin P Dullaart; José A Sgarbi; Graziano Ceresini; Rui M B Maciel; Rudi G Westendorp; J Wouter Jukema; Misa Imaizumi; Jayne A Franklyn; Douglas C Bauer; John P Walsh; Salman Razvi; Kay-Tee Khaw; Anne R Cappola; Henry Völzke; Oscar H Franco; Jacobijn Gussekloo; Nicolas Rodondi; Robin P Peeters Journal: J Clin Endocrinol Metab Date: 2015-04-09 Impact factor: 5.958
Authors: Jihye Park; Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Anne C Kirchhoff; Dev Abraham; Jaewhan Kim; Marcus Monroe; Mia Hashibe Journal: J Clin Endocrinol Metab Date: 2018-07-01 Impact factor: 5.958
Authors: Xiaodong Liu; Carlos K H Wong; Wendy W L Chan; Eric H M Tang; Yu Cho Woo; Shirley Y W Liu; Cindy L K Lam; Brian H H Lang Journal: BJS Open Date: 2022-07-07
Authors: Nermin Diab; Natalie R Daya; Stephen P Juraschek; Seth S Martin; John W McEvoy; Ulla T Schultheiß; Anna Köttgen; Elizabeth Selvin Journal: Sci Rep Date: 2019-09-11 Impact factor: 4.379
Authors: Bruce H R Wolffenbuttel; Hanneke J C M Wouters; M Rebecca Heiner-Fokkema; Melanie M van der Klauw Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-05-27
Authors: Maria Papaleontiou; Deborah A Levine; David Reyes-Gastelum; Sarah T Hawley; Mousumi Banerjee; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134